Evaluation of the GlucoTrack, Non-Invasive Glucose Monitoring Device
Launched by INTEGRITY APPLICATIONS LTD. · Feb 9, 2007
Trial Information
Current as of May 20, 2025
Unknown status
Keywords
ClinConnect Summary
Diabetes is a leading cause of death in the Western World with medical costs increasing annually. There is no cure for diabetes, and blood glucose monitoring is a key component in diabetes treatment and management. Consistently high blood sugar levels can, over time, lead to complications such as blindness, kidney disease, heart disease, and nerve damage.In addition, low blood sugars may lead to immediate dangers. Self-monitoring of blood glucose levels is essential to the self-management of diabetes and has become widespread over the past decade. Blood glucose determinations are currently ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with Type 1, Type 2, or Gestational Diabetes
- • Above the age of 10
- Exclusion Criteria:
- • Does not meet inclusion criteria
- • Patients requiring dialysis
- • Participation in other clinical investigations within the previous month.
- • Pregnancy(excluding patients that intend to participate in the gestational group)
About Integrity Applications Ltd.
Integrity Applications Ltd. is a pioneering clinical trial sponsor focused on advancing innovative medical technologies to improve patient outcomes in the management of diabetes. With a commitment to rigorous research and development, the company specializes in non-invasive glucose monitoring solutions that enhance the quality of life for individuals living with diabetes. Integrity Applications Ltd. collaborates closely with healthcare professionals and regulatory bodies to ensure the highest standards of safety and efficacy in its trials, ultimately aiming to deliver cutting-edge solutions that empower patients and transform diabetes care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beer Sheva, , Israel
Patients applied
Trial Officials
Ilana Harman-Boehm, MD
Principal Investigator
Soroka University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials